GRI Bio Inc. (GRI)
0.74
0.01 (1.37%)
At close: Jan 14, 2025, 3:59 PM
0.71
-3.89%
After-hours Jan 14, 2025, 07:52 PM EST
Company Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States.
Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder.
GRI Bio, Inc. was formerly known as Glycoregimmune, Inc.
GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Bio Inc.
| Country | United States |
| IPO Date | Feb 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Cristina Gil White |
Contact Details
Address: 2223 Avenida de la Playa LA Jolla, California United States | |
| Website | https://www.gribio.com |
Stock Details
| Ticker Symbol | GRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000084112 |
| CUSIP Number | n/a |
| ISIN Number | US3622AW2059 |
| Employer ID | 84-0524756 |
| SIC Code | 3669 |
Key Executives
| Name | Position |
|---|---|
| Cristina Gil White | Interim Chief Executive Officer |
| Leanne M. Kelly | Chief Financial Officer & Corporate Secretary |
| Dr. Albert Agro Ph.d. | Co-Founder & Chief Medical Officer |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. W. Marc Hertz Ph.D. | President & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 10-Q | Quarterly Report |
| Sep 16, 2024 | 10-Q | Quarterly Report |
| Aug 15, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 10-K | Annual Report |
| Jul 29, 2024 | NT 10-K | Filing |
| Mar 15, 2024 | 10-Q | Quarterly Report |